Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.36 |
| ▸ | LCK | P06239 | 10/20 | 0.36 |
| ▸ | FYN | P06241 | 10/20 | 0.36 |
| ▸ | YES1 | P07947 | 10/20 | 0.36 |
| ▸ | KDR | P35968 | 10/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408140 | 0.92 | SRC (0.41) | SRCLCKFYNYES1KDR | |
| SCHEMBL5406462 | 0.90 | SRC (0.42) | SRCLCKFYNYES1KDR | |
| SCHEMBL5414923 | 0.81 | SRC (0.44) | SRCLCKFYNYES1KDR | |
| SCHEMBL5421085 | 0.80 | SRC (0.42) | SRCLCKFYNYES1KDR | |
| SCHEMBL5403350 | 0.78 | SRC (0.33) | SRCLCKFYNYES1KDR | |
| SCHEMBL5399026 | 0.76 | SRC (0.53) | SRCLCKFYNYES1KDR | |
| SCHEMBL6606058 | 0.73 | SRC (0.50) | SRCLCKFYNYES1KDR | |
| SCHEMBL6615698 | 0.72 | SRC (0.44) | SRCLCKFYNYES1KDR | |
| SCHEMBL6602200 | 0.72 | SRC (0.53) | SRCLCKFYNYES1KDR | |
| SCHEMBL5401598 | 0.72 | SRC (0.52) | SRCLCKFYNYES1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984930-B1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | SUGEN INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| US-6133305-A | PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | SRC 260/4885LCK 357/4885FYN 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.